TACSTD2 and ovarian carcinoma: To assess the binding specificity of FOLR1-, TROP2-, and TF-targeted pre-targeting complex for NIR-PIT, ovarian cancer cell lines (SKOV3, OVCAR3, IGROV1, and A2780) were incubated with scFv-Farletuzumab-Zip2, scFv-Sacituzumab-Zip2, and scFv-Tisotumab-Zip2, followed by incubation with Zip1-SNAP-IR700, and analyzed via flow cytometry.